42 related articles for article (PubMed ID: 10702820)
21. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
[TBL] [Abstract][Full Text] [Related]
22. A phase II study of subcutaneous low-dose interleukin-2 plus erythropoietin in metastatic renal cell carcinoma progressing on interleukin-2 alone.
Lissoni P; Rovelli F; Baiocco N; Tangini G; Fumagalli L
Anticancer Res; 2001; 21(1B):777-9. PubMed ID: 11299843
[TBL] [Abstract][Full Text] [Related]
23. Serum levels of interleukins 2, 6 and 8, soluble interleukin-2 receptor and intercellular adhesion molecule-1 during treatment with interleukin-2 plus interferon-alfa.
Vuoristo MS; Kellokumpu-Lehtinen P; Laine S; Soppi E
Immunopharmacol Immunotoxicol; 1996 Aug; 18(3):337-54. PubMed ID: 8872489
[TBL] [Abstract][Full Text] [Related]
24. Subcutaneous interleukin-2 and interferon alfa administration in patients with metastatic renal cell carcinoma: final results of SCAPP III, a large, multicenter, phase II, nonrandomized study with sequential analysis design--the Subcutaneous Administration Propeukin Program Cooperative Group.
Tourani JM; Pfister C; Tubiana N; Ouldkaci M; Prevot G; Lucas V; Oudard S; Malet M; Cottu P; Ferrero JM; Mayeur D; Rixe O; Sun XS; Bernard O; Andre T; Tournigand C; Muracciole X; Guilhot J;
J Clin Oncol; 2003 Nov; 21(21):3987-94. PubMed ID: 14581421
[TBL] [Abstract][Full Text] [Related]
25. Low doses of subcutaneous interleukin-2 plus interferon-alpha do not induce thyroid function alterations in advanced renal cell carcinoma patients.
Sartore-Bianchi A; Soriani A; Mattioni R; Vaglio A; Buzio C; Porta C
Oncol Rep; 2004 Oct; 12(4):855-9. PubMed ID: 15375512
[TBL] [Abstract][Full Text] [Related]
26. Effects of low-dose recombinant interleukin-2 in human malignancies.
Lissoni P
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S115-20. PubMed ID: 9457406
[TBL] [Abstract][Full Text] [Related]
27. Rethinking Oncologic Treatment Strategies with Interleukin-2.
Ko B; Takebe N; Andrews O; Makena MR; Chen AP
Cells; 2023 May; 12(9):. PubMed ID: 37174716
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of routes of administration of interferon in cancer: a review and a proposal.
Bocci V
Cancer Drug Deliv; 1984; 1(4):337-51. PubMed ID: 6085757
[TBL] [Abstract][Full Text] [Related]
29. Opposing roles of eosinophils in cancer.
Simon SCS; Utikal J; Umansky V
Cancer Immunol Immunother; 2019 May; 68(5):823-833. PubMed ID: 30302498
[TBL] [Abstract][Full Text] [Related]
30. Intravenous ascorbic acid as an adjuvant to interleukin-2 immunotherapy.
Wagner SC; Markosian B; Ajili N; Dolan BR; Kim AJ; Alexandrescu DT; Dasanu CA; Minev B; Koropatnick J; Marincola FM; Riordan NH
J Transl Med; 2014 May; 12():127. PubMed ID: 24884532
[TBL] [Abstract][Full Text] [Related]
31. Eosinophils and melanoma: Implications for immunotherapy.
Robinson I; Santa Lucia G; Li A; Oberholtzer N; Plante J; Quinn KM; Reuben D; Mehrotra S; Valdebran M
Pigment Cell Melanoma Res; 2022 Mar; 35(2):192-202. PubMed ID: 34927354
[TBL] [Abstract][Full Text] [Related]
32. Eosinophils and C4 predict clinical failure of combination immunotherapy with very low dose subcutaneous interleukin-2 and interferon in renal cell carcinoma patients.
Moroni M; Porta C; De Amici M; Quaglini S; Cattabiani MA; Buzio C
Haematologica; 2000 Mar; 85(3):298-303. PubMed ID: 10702820
[TBL] [Abstract][Full Text] [Related]
33. Interleukin-2 based immunotherapy in patients with metastatic renal cell carcinoma.
Donskov F
Dan Med Bull; 2007 Nov; 54(4):249-65. PubMed ID: 18208677
[TBL] [Abstract][Full Text] [Related]
34. Which immunological parameters are clinically essential to monitor IL-2 cancer immunotherapy?
Lissoni P; Brivio F; Viviani S; Fumagalli L
J Biol Regul Homeost Agents; 1999; 13(2):110-4. PubMed ID: 10503734
[TBL] [Abstract][Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
